Calidi Biotherapeutics (CLDI) Receivables - Other (2022 - 2025)
Calidi Biotherapeutics' quarterly Receivables - Other came in at $50.0 billion in Q4 2025, up 24999900.0% year-on-year from N/an in Q4 2024, and up 99999900.0% quarter-over-quarter from $50000.0 in Q2 2025.
Calidi Biotherapeutics has reported Receivables - Other for 4 years, with the latest figure at $50.0 billion in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other rose 24999900.0% year-over-year to $50.0 billion; the trailing twelve-month figure through Dec 2025 stood at $50.0 billion (up 24999900.0% YoY), and the FY2025 full-year result was $50.0 billion, up 24999900.0% from the prior year.
- Receivables - Other for Q4 2025 stood at $50.0 billion, up from $50000.0 in the prior quarter.
- The five-year high for Expense - Property Taxes and Insurance was $404000.0 in Q2 2024, with the low at $134000.0 in Q3 2025.
- Average Receivables - Other over 4 years is $6.3 billion, with a median of $125000.0 recorded in 2024.
- Year-over-year, Receivables - Other plunged 93.1% in 2024 and soared 24999900.0% in 2025.
- Tracing CLDI's Receivables - Other over 4 years: stood at $870.0 in 2022, then soared by 333233.33% to $2.9 million in 2023, then sank by 93.1% to $200000.0 in 2024, then soared by 24999900.0% to $50.0 billion in 2025.
- The last three Receivables - Other figures came in at $50.0 billion (Q4 2025), $50000.0 (Q2 2025), and $50000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Calidi Biotherapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50.00 Bn |
| Dec 31, 2025 | 50.00 Bn |
| Jun 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Dec 31, 2023 | 2.90 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Mar 31, 2023 | 870.00 |
| Mar 31, 2023 | 870.00 |
| Dec 31, 2022 | 870.00 |
| Dec 31, 2022 | 870.00 |